

**WHO Prequalification Programme**  
**WHO PUBLIC ASSESSMENT REPORT (WHOPAR)**

**[NT022 trade name]\***

Praziquantel 600 mg film-coated tablets

[NT022 trade name], manufactured at Mepro Pharmaceuticals Pvt. Ltd., Vadodara, Gujarat, India, was included in the WHO list of prequalified medicinal products for the treatment of neglected tropical disease on 19 June 2026.

[NT022 trade name] is indicated for the parasitic infections of schistosomiasis, taeniasis, neurocysticercosis, clonorchiasis, opisthorchiasis, and paragonimiasis. Detailed information on the use of this product is described in the summary of product characteristics (SmPC), which can be found in this WHOPAR.

The active pharmaceutical ingredient of [NT022 trade name] is praziquantel.

The efficacy and safety of praziquantel is well established based on extensive clinical experience in the treatment of neglected tropical disease.

For details on the uses of this product and for side effects and warnings, see Part 4 of this WHOPAR (summary of product characteristics).

On the basis of data submitted and public information on the use of praziquantel in neglected tropical disease, the team of assessors advised that [NT022 trade name] is of acceptable quality, efficacy and safety to allow inclusion of [NT022 trade name] in the list of prequalified medicinal products.

**Summary of prequalification status for [NT022 trade name]:**

The table shows the status of relevant completed activities, including the dates of WHO internal quality assurance.

---

\* Trade names are not prequalified by WHO. This is the national medicines regulatory authority's responsibility.

| Initial acceptance                                                                                                                                                                                                                                                                                                                                                                                                                                               | Date              | Outcome |
|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------|---------|
| Status on PQ list                                                                                                                                                                                                                                                                                                                                                                                                                                                | 19 June 2026      | listed  |
| Pharmaceutical quality                                                                                                                                                                                                                                                                                                                                                                                                                                           | 26 May 2026       | MR      |
| Bioequivalence                                                                                                                                                                                                                                                                                                                                                                                                                                                   | 28 May 2026       | MR      |
| Safety, efficacy                                                                                                                                                                                                                                                                                                                                                                                                                                                 | NA                | NA      |
| <b>GMP (re-)inspection</b>                                                                                                                                                                                                                                                                                                                                                                                                                                       |                   |         |
| API                                                                                                                                                                                                                                                                                                                                                                                                                                                              | 23 September 2025 | MR*     |
| FPP                                                                                                                                                                                                                                                                                                                                                                                                                                                              | 26 January 2026   | MR*     |
| <b>GCP/GLP (re-)inspection</b>                                                                                                                                                                                                                                                                                                                                                                                                                                   | 12 September 2025 | MR      |
| <div> <div> API: active pharmaceutical ingredient<br/> FPP: finished pharmaceutical product<br/> GCP: good clinical practice<br/> [quality standard]<br/> GLP: good laboratory practice<br/> [quality standard] </div> <div> GMP: good manufacturing practice<br/> [quality standard]<br/> MR: meets requirements<br/> MR*: desk review<br/> (based on recent inspection reports)<br/> NA: not applicable, not available<br/> PQ: prequalification </div> </div> |                   |         |